IL6 and interstitial lung disease: Furthermore, thalidomide reduces lipopolysaccharide‐stimulated release of TNF‐α, IL‐8, and IL‐18 (‘necrotic’ cytokines), but not IL‐6, IL‐10, and IL‐12 (p70) (‘inflammatory’ cytokines) from alveolar macrophages in patients with interstitial lung disease.39